

THE CLAIMS

We claim:

1. A pharmaceutical composition comprising two or more therapeutic agents selected from the group consisting of:
 - (a) azo-bonded 4-APAA compound;
 - (b) non-azo bonded 4-APAA compound;
 - (c) azo-bonded 5-ASA compound;
 - (d) non-azo bonded 5-ASA compound;
 - (e) 4-APAA compound azo bonded to a 5-ASA compound.
2. The pharmaceutical composition of claim 1 further comprising a third therapeutic agent selected from the group consisting of: steroids, antibiotics,
3. The pharmaceutical composition of claim 1 formulated to deliver the therapeutic agents to the small intestine and/or the colon.
4. The pharmaceutical composition of claim 1 formulated to release the therapeutic agents along the length of the small intestine and the colon.
5. The pharmaceutical composition of claim 1 formulated to release the therapeutic agents along the length of the distal portion of the small intestine and the colon.
6. The pharmaceutical composition of claim 1 formulated to release the therapeutic agents along the length of the colon.
7. The pharmaceutical composition of claim 1 formulated to pass through the stomach and to release the active agent in the intestine.
8. The pharmaceutical composition of claim 1 formulated as a suppository.
9. The pharmaceutical composition of claim 1 formulated for administration as an enema.
10. The pharmaceutical composition of claim 1 formulated as a mouth wash.
11. The pharmaceutical composition of claim 1 formulated for vaginal administration.

12. The pharmaceutical composition of claim 1 formulated for intra-uterine administration.

13. The pharmaceutical composition of claim 1 formulated for topical administration.

14. The pharmaceutical composition of claim 1 formulated for administration to the eye.

15. The pharmaceutical composition of claim 1 formulated to release:

(a) at least one component selected from:

(i) a first component comprising one or more of the therapeutic agents formulated for release in the stomach,

(ii) a second component comprising one or more of the therapeutic agents formulated for release in the small intestine or distal portion of the small intestine, and

(b) a third component comprising one or more of the therapeutic agents formulated for release in the colon.

16. The pharmaceutical composition of claim 15 wherein:

(a) the first component comprises a 5-ASA compound;

(b) the second component comprises a 5-ASA compound and a 4-APAA compound formulated for release in a distal portion of the small intestine;

(c) the third component comprises a 5-ASA compound and a 4-APAA compound.

17. The pharmaceutical composition of claim 15 wherein:

(a) the first component comprises a 5-ASA compound;

(b) the second component comprises:

(i) a 5-ASA compound formulated for release in the small intestine;

(ii) a 5-ASA compound and a 4-APAA compound formulated for release in a distal portion of the small intestine;

(c) the third component comprises a 5-ASA compound and a 4-APAA compound.

18. The pharmaceutical composition of claim 15 wherein:

(a) the first component comprises a 5-ASA compound;

- (b) the second component is not present;
- (c) the third component comprises a 5-ASA compound and a 4-APAA compound.

19. The pharmaceutical composition of claim 15 wherein:

- (a) the first component comprises a 5-ASA compound;
- (b) the second component comprises a 5-ASA compound formulated for release in the small intestine ;
- (c) the third component comprises a 5-ASA compound and a 4-APAA compound.

20. The pharmaceutical composition of claim 15 wherein:

- (a) the first component comprises a 4-APAA compound;
- (b) the second component comprises a 5-ASA compound and a 4-APAA compound formulated for release in a distal portion of the small intestine;
- (c) the third component comprises a 5-ASA compound and a 4-APAA compound.

21. The pharmaceutical composition of claim 15 wherein:

- (a) the first component comprises a 4-APAA compound;
- (b) the second component comprises:
 - (i) a 4-APAA compound formulated for release in the small intestine; and
 - (ii) a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine;
- (c) the third component comprises a 5-ASA compound and a 4-APAA compound.

22. The pharmaceutical composition of claim 15 wherein:

- (a) the first component comprises a 4-APAA compound;
- (b) the second component is not present;
- (c) the third component comprises a 5-ASA compound and a 4-APAA compound.

23. The pharmaceutical composition of claim 15 wherein:

- (a) the first component comprises a 4-APAA compound;
- (b) the second component comprises a 4-APAA compound formulated for release in the small intestine;
- (c) the third component comprises a 5-ASA compound and a 4-APAA compound.

24. The pharmaceutical composition of claim 15 wherein:

- (a) the first component is not present;
- (b) the second component comprises a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine;
- (c) the third component comprises a 5-ASA compound and a 4-APAA compound.

25. The pharmaceutical composition of claim 15 wherein:

- (a) the first component is not present;
- (b) the second component comprises:
 - (i) a 5-ASA compound formulated for release in the small intestine;
 - (ii) a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine;
- (c) the third component comprises a 5-ASA compound and a 4-APAA compound.

26. The pharmaceutical composition of claim 15 wherein:

- (a) the first component is not present;
- (b) the second component comprises a 5-ASA compound formulated for release in the small intestine;
- (c) the third component comprises a 5-ASA compound and a 4-APAA compound.

27. The pharmaceutical composition of claim 15 wherein:

- (a) the first component is not present;
- (b) the second component comprises a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine;

(c) the third component comprises a 5-ASA compound and a 4-APAA compound.

28. The pharmaceutical composition of claim 15 wherein:

(a) the first component is not present;

(b) the second component comprises:

(i) a 4-APAA compound formulated for release in the small intestine; and

(ii) a 5-ASA compound and 4-APAA compound formulated for release in a distal portion of the small intestine;

(c) the third component comprises a 5-ASA compound and a 4-APAA compound.

29. The pharmaceutical composition of claim 15 wherein:

(a) the first component is not present;

(b) the second component comprises a 4-APAA compound formulated for release in the small intestine;

(c) the third component comprises a 5-ASA compound and a 4-APAA compound.

30. A method of treating an inflammatory gastrointestinal condition comprising administering to a subject in need thereof a pharmaceutical composition of any of 1-29.

31. Use of a pharmaceutical composition of any of claims 1-29 in the manufacture of a medicament for treatment of an inflammatory gastrointestinal condition.